All News
The EULAR 2015 Report- Friday
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
Read ArticleThe EULAR 2015 Report - Thursday
These abstracts and presentations were presented Thursday 11 June at the EULAR 2015 annual meeting.
Read ArticleThe EULAR 2015 Report - Wednesday
EULAR 2015 started the afternoon of Wednesday June 10th.
Read ArticleAllopurinol Reduces Mortality in Gout
CVD risk is significantly augmented in gout. Choi and coworkers studied this issue using a UK general population database using an incident user cohort study with propensity score matching.
Read ArticleHigh Flare Rates with Drug Withdrawal in JIA
While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.
Read ArticleTofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose
A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.
Read ArticleNonadherence to Self-Injected Biologics is High
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Read ArticleAmgen Halts Development of Brodalumab
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
Read ArticleSildenafil May Help Heal Scleroderma Ulcers
A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.
Read ArticleRA Sarilumab Trials Meet Primary Endpoints
Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.
Read ArticleAmgen & Abbvie Increase the Price of TNF Inhibitors
The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.
Read Article
A Microneedle Pill as an Alternative to Injectable Drug
Carl Schoellhammerhas just won the Lemelson-MIT National Collegiate Student Prize for his invention - the microneedle pill.
Read ArticleAdalimumab Gets FDA Orphan Drug Status for Use in Hidradenitis Suppurativa
The FDA has granted adalimumab (Humira) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease).
Read ArticleEarly DMARD Therapy Averts Cardiovascular Risk in RA
A Finnish early RA register studied 14,878 incident RA patients from 2000-2008 and identified 1157 deaths. Patients receiving DMARDs and MTX had lower mortality rates. The standardized moratility ratio for the entire cohort was reduced (0.57, 95% CI 0.52 to 0.62).
Read ArticleEconomic Impact of Biosimilars
According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022.
Read ArticleHepatotoxicity and TNF Inhibitors
Hepatic enzyme elevations with TNF inhibitor use is not uncommon.
Read ArticleRA Compliance Undermines Treatment Success
Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.
Read ArticleZoster Risk is Similar Among Different MOA Biologics
The risk of new H zoster infection was studied among nearly 30,000 new biologic starts and compared rates seen with abatacept, adalimumab, rituximab, infliximab, etanercept, tocilizumab, certolizumab or golimumab initiation.
Read ArticleAS vs. SpA Responses with Combination Treatment
Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.
Read Article